Factors of vascular endothelial dysfunction and thrombogenic risk in patients with chronic obstructive pulmonary disease in combination with obstructive sleep apnea after an exacerbation

Obstructive sleep apnea (OSA) is a common disease. The incidence is higher in patients with chronic obstructive pulmonary disease with moderate to severe bronchial obstruction or hypoxemia. OSA is associated with increased risks of fatal outcomes of acute cardiovascular diseases in such patients. Objective. To assess the effect of long-term non-invasive ventilation of the lungs in the spontaneous breathing mode with positive airway pressure (CPAP) on the indicators of systemic inflammation, insulin resistance, and thrombogenic risk together with clinical outcomes during the rehabilitation period after an exacerbation in patients with concomitant chronic obstructive pulmonary disease and obstructive sleep apnea who do not need long-term oxygen therapy. Methods. The effects of long-term CPAP therapy as a part of complex treatment were analyzed in an openlabel, prospective, comparative six-week study that enrolled 65 patients with concomitant chronic obstructive pulmonary disease and obstructive sleep apnea. The main group included 26 people who received CPAP therapy as a part of complex treatment. The comparison group included 39 people who did not use non-invasive ventilation of the lungs. The patients’ age was 55.5 ± 2.1 years in the main group and 57.1 ± 1.5 years in the comparison group (p > 0.1). Men prevailed in both groups – 92.3% in the main group and 100.0% in the comparison group (p > 0.1). Results. The clinical efficacy of CPAP therapy was confirmed by an improvement in the quality of life of patients on the SF-36 questionnaire, a decrease in the degree of daytime sleepiness on the Epworth scale (Johns, 1991). CPAP-therapy was associated with a drop in the serum levels of tumor necrosis factor α and the blood level of endothelin 1, a more pronounced decrease in the levels of C-reactive protein, interleukin 8, C-peptide, vascular endothelial growth factor, homocysteine versus the comparison group. Conclusion. The use of CPAP-therapy in patients with concomitant chronic obstructive pulmonary disease and obstructive sleep apnea who do not need long-term oxygen therapy during the rehabilitation period after an exacerbation is associated with a decrease in systemic inflammation, vascular endothelial dysfunction, and hyperhomocysteinemia.

1. Soler X., Gaio E., Powell F.L. et al. High prevalence of obstructive sleep apnea in patients with moderate to severe chronic obstructive pulmonary disease. Ann. Am. Thorac. Soc. 2015; 12 (8): 1219–1225. DOI: 10.1513/AnnalsATS.201407-336OC.

2. Gunduz C., Basoglu O.K., Tasbakan M.S. Prevalence of overlap syndrome in chronic obstructive pulmonary disease patients without sleep apnea symptoms. Clin. Respir. J. 2018; 12 (1): 105–112. DOI: 10.1111/crj.12493.

3. Alekseeva O.V., Demko I.V., Shnayder N.A., Petrova M.M. [Comorbidity obstructive sleep apnea/hypopnea syndrome and chronic obstructive pulmonary disease]. Zabaykal’skiy meditsinskiy vestnik. 2016; 2: 107–114 (in Russian).

4. McNicholas W.T. Comorbid obstructive sleep apnoea and chronic obstructive pulmonary disease and the risk of cardiovascular disease. J. Thorac. Dis. 2018; 10 (Suppl. 34): S4253–4261. DOI: 10.21037/jtd.2018.10.117.

5. Xie J., Li F., Wu X., Hou W. Prevalence of pulmonary embolism in patients with obstructive sleep apnea and chronic obstructive pulmonary disease: The overlap syndrome. Heart Lung. 2019; 48 (3): 261–265. DOI: 10.1016/j.hrtlng.2018.11.001.

6. Lacedonia D., Carpagnano G.E., Aliani M. et al. Daytime PaO2 in OSAS, COPD and the combination of the two (overlap syndrome). Respir. Med. 2013; 107 (2): 310–316. DOI: 10.1016/j.rmed.2012.10.012.

7. Du W., Liu J., Zhou J. et al. Obstructive sleep apnea, COPD, the overlap syndrome, and mortality: results from the 2005–2008 National Health and Nutrition Examination Survey. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 665–674. DOI: 10.2147/COPD.S148735.

8. Gottlieb D.J., Punjabi N.M., Mehra R. et al. CPAP versus oxygen in obstructive sleep apnea. N. Engl. J. Med. 2014; 370 (24): 2276–2285. DOI: 10.1056/NEJMoa1306766.

9. Singh G., Agarwal A., Zhang W. et al. Impact of PAP therapy on hospitalization rates in Medicare beneficiaries with COPD and coexisting OSA. Sleep Breath. 2019; 23 (1): 193–200. DOI: 10.1007/s11325-018-1680-0.

10. Barbe F., Pépin J.L., ed. Obstructive Sleep Apnoea. ERS Monograph [Еlectronic resource]; 2015. DOI: 10.1183/2312508X.erm6715.

11. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2014. Available at: https://goldcopd.org

12. Novik A.A., Ionova T.I. [Guideline to the study of the quality of life in medicine]. Moscow: OLMA-PRESS; 2002 (in Russian).

13. Amirdzhanova V.N., Goryachev D.V., Korshunov N.I. et al. [SF-36 questionnaire population quality of life indices objective]. Nauchno-prakticheskaya revmatologiya. 2008; 46 (1): 36–48. Available at: https://cyberleninka.ru/article/n/populyatsionnye-pokazateli-kachestva-zhizni-po-oprosniku-sf-36-rezultaty-mnogotsentrovogo-issledovaniya-kachestva-zhizni-mirazh/viewer [Accessed: August 25, 2020] (in Russian).

14. Chazova I. E., Martynyuk T. V., Avdeev S.N. et al. [National clinical guideline on diagnosis and treatment of pulmonary hypertension]. Evraziyskiy kardiologicheskiy zhurnal. 2014; (4): 4–24. Available at: https://cyberleninka.ru/article/n/klinicheskie-rekomendatsii-po-diagnostike-i-lecheniyu-legochnoy-gipertenzii [Accessed: August 25, 2020] (in Russian).

15. Toraldo D.M., De Benedetto M., Scoditti E., De Nuccio F. Obstructive sleep apnea syndrome: coagulation anomalies and treatment with continuous positive airway pressure. Sleep Breath. 2016; 20 (2): 457–465. DOI: 10.1007/s11325-015-1227-6.

16. Akinnusi M.E., Paasch L.L., Szarpa K.R. et al. Impact of nasal continuous positive airway pressure therapy on markers of platelet activation in patients with obstructive sleep apnea. Respiration. 2009; 77 (1): 25–31. DOI: 10.1159/000158488.

17. Phillips C.L., McEwen B.J., Morel-Kopp M.C. et al. Effects of continuous positive airway pressure on coagulability in obstructive sleep apnoea: a randomised, placebo-controlled crossover study. Thorax. 2012; 67 (7): 639–644. DOI: 10.1136/thoraxjnl-2011-200874.

18. Voelkel N. F., Gomez-Arroyo J. The role of vascular endothelial growth factor in pulmonary arterial hypertension. The angiogenesis paradox. Am. J. Respir. Cell. Mol. Biol. 2014; 51 (4): 474–484. DOI: 10.1165/rcmb.2014-0045TR.

19. Heil S.G., Den Heijer M., Van der Rijt-Pisa B.J.M. et al. The 894 G > T variant of endothelial nitric oxide synthase (eNOS) increases the risk of recurrent venous thrombosis through interaction with elevated homocysteine levels. J. Thromb. Haemost. 2004; 2 (5): 750–753. DOI: 10.1111/j.1538-7836.2004.00701.x.

20. Santilli F., Davì G., Patrono C. Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: A mechanistic and clinical perspective. Vasc. Pharmacol. 2016; 78: 1–9. DOI: 10.1016/j.vph.2015.06.009.